Skip to content

Study · Not a test of the peptide alone · 1991

6 results

Lack of effect of vasoactive intestinal peptide antagonists on blood flow in the rat thyroid.

Michalkiewicz M, Huffman LJ, Hedge GA

Peptides1 Nov 1991Cited by 3 (Europe PMC)

PMID1815206 (opens in a new tab)DOI10.1016/0196-9781(91)90192-r (opens in a new tab)PepBankPUB-01815206
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Efficacy outcome

    In anesthetized rats, VIP administration increased thyroid blood flow.

    In plain wordsIn rats, VIP given by injection raised blood flow in the thyroid gland.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseThyroid blood flow after VIP
    Study

    ratn: not reported in source

    Ketamine-pentobarbital-anesthetized rats
    Outcome group
    Vascular function · Endocrine and hormones

    Source sentences

    Summary
    Increases in thyroid BF induced by VIP administration (30 pmol-1.5 nmol/100 g b.wt.)

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In anesthetized rats, three putative VIP antagonists did not affect the increase in thyroid blood flow induced by VIP.

    In plain wordsIn rats, three VIP-blocking compounds did not stop VIP from raising thyroid blood flow.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeVIP-induced thyroid blood flow with VIP antagonists
    Study

    ratn: not reported in source

    Ketamine-pentobarbital-anesthetized rats
    Outcome group
    Vascular function · Endocrine and hormones

    Source sentences

    Summary
    Increases in thyroid BF induced by VIP administration (30 pmol-1.5 nmol/100 g b.wt.) were not affected by any of the three compounds tested at doses 10-100 times higher than that of VIP.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Efficacy outcome

    In anesthetized rats, VIP administration increased pancreatic blood flow.

    In plain wordsIn rats, VIP given by injection raised blood flow in the pancreas.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePancreatic blood flow after VIP
    Study

    ratn: not reported in source

    Ketamine-pentobarbital-anesthetized rats
    Outcome group
    Vascular function · Gastrointestinal

    Source sentences

    Summary
    Increases in pancreatic and salivary gland BFs induced by VIP (30 pmol/100 g b.wt.)

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  4. 04AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Efficacy outcome

    In anesthetized rats, VIP administration increased salivary gland blood flow.

    In plain wordsIn rats, VIP given by injection raised blood flow in the salivary glands.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseSalivary gland blood flow after VIP
    Study

    ratn: not reported in source

    Ketamine-pentobarbital-anesthetized rats
    Outcome group
    Vascular function · Gastrointestinal

    Source sentences

    Summary
    Increases in pancreatic and salivary gland BFs induced by VIP (30 pmol/100 g b.wt.)

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  5. 05AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In anesthetized rats, two putative VIP antagonists did not affect the VIP-induced increase in pancreatic blood flow.

    In plain wordsIn rats, two VIP-blocking compounds did not stop VIP from raising pancreatic blood flow.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeVIP-induced pancreatic blood flow with VIP antagonists
    Study

    ratn: not reported in source

    Ketamine-pentobarbital-anesthetized rats
    Outcome group
    Vascular function · Gastrointestinal

    Source sentences

    Summary
    Increases in pancreatic and salivary gland BFs induced by VIP (30 pmol/100 g b.wt.) were also not affected by [4C1-D-Phe6,Leu17]VIP or [N-Ac-Tyr1,D-Phe2]GRF(1-29)-NH2 (3 nmol/100 g b.wt.).

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  6. 06AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In anesthetized rats, two putative VIP antagonists did not affect the VIP-induced increase in salivary gland blood flow.

    In plain wordsIn rats, two VIP-blocking compounds did not stop VIP from raising salivary gland blood flow.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeVIP-induced salivary gland blood flow with VIP antagonists
    Study

    ratn: not reported in source

    Ketamine-pentobarbital-anesthetized rats
    Outcome group
    Vascular function · Gastrointestinal

    Source sentences

    Summary
    Increases in pancreatic and salivary gland BFs induced by VIP (30 pmol/100 g b.wt.) were also not affected by [4C1-D-Phe6,Leu17]VIP or [N-Ac-Tyr1,D-Phe2]GRF(1-29)-NH2 (3 nmol/100 g b.wt.).

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 38Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 12:41 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.